ClinVar Miner

Submissions for variant NM_005633.3(SOS1):c.1656G>C (p.Arg552Ser) (rs267607079)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen RASopathy Variant Curation Expert Panel RCV000787998 SCV000927029 pathogenic Noonan syndrome and Noonan-related syndrome 2019-05-10 reviewed by expert panel curation The c.1656G>C (p.Arg552Ser) variant in SOS1 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 17143282). This variant has also been identified in at least 7 independent occurrences in patients with clinical features of a RASopathy (PS4; PMIDs: 26297936, 25862627, 17143282, 21387466, 19020799, 23885229, 22190897, 19352411). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). In vitro functional studies provide some evidence that the p.Arg552Ser variant may impact protein function (PS3; PMID: 27304678). This residue has been identified as a hot spot. These variants would have received PM5_Strong but the RAS EP decided that PM1 and PM5 cannot be used simultaneously and therefore this rule has been upgraded with expert judgement (PM1_Strong). Computational prediction tools and conservation analysis suggest that the p.Arg552Ser variant may impact the protein (PP3). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS4, PM2, PS3, PM1_Strong, PP2, PP3.
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000156992 SCV000062202 pathogenic Noonan syndrome 2013-09-24 criteria provided, single submitter clinical testing The Arg552Ser variant in SOS1 has been identified in 7 individuals with either t he clinical features of Noonan syndrome or Noonan syndrome associated with multi ple giant-cell lesions, and occurred de novo in one of these individuals (Slezak 2010, Beneteau 2009, Tartaglia 2007, LMM unpublished data). This variant has al so not been identified in large population studies. In addition, multiple other variants affecting this position (Arg552Gly, Arg552Lys, Arg552Met, Arg552Thr) ha ve been reported in individuals with Noonan syndrome, and functional studies sho wed that another variant at the same position (Arg552Gly) caused increased and p rolonged RAS activation (Tartaglia 2007). In summary, the Arg552Ser variant meet s our criteria to be classified as pathogenic (http://pcpgm.partners.org/LMM) ba sed on de novo occurrence, absence from controls, and supporting functional evid ence.
GeneDx RCV000159177 SCV000209122 pathogenic not provided 2017-10-25 criteria provided, single submitter clinical testing The R552S variant has been published as a de novo pathogenic variant for Noonan syndrome and as a pathogenic variant for an allelic disorder, Noonan like/Multiple Giant Cell Lesion syndrome (Tartaglia et al., 2007; Beneteau et al., 2009; Neumann et al., 2009). The R552S variant is not observed in large population cohorts (Lek et al., 2016). The R552S variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species and that is a recognized hot spot" for pathogenic variants within the SOS1 gene. Pathogenic missense variants in the same residue (R552G, R552T, R552K, R552M) have been reported in the Human Gene Mutation Database in association with Noonan syndrome (Stenson et al., 2014). In silico analysis predicts this variant is probably damaging to the protein structure/function. In summary, this variant is pathogenic."
Invitae RCV000654947 SCV000776855 pathogenic Rasopathy 2019-09-27 criteria provided, single submitter clinical testing This sequence change replaces arginine with serine at codon 552 of the SOS1 protein (p.Arg552Ser). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and serine. This variant is not present in population databases (ExAC no frequency). This variant has been reported in several individuals affected with Noonan syndrome (PMID: 21387466, 24037001, 19020799, 22190897, 19352411, 23885229), including 2 affected individuals in which this variant was reported to be de novo (PMID: 17143282). ClinVar contains an entry for this variant (Variation ID: 12872). Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). A different variant (c.1656G>T) giving rise to the same protein effect observed here (p.Arg552Ser) has been reported in several individuals affected with Noonan syndrome (PMID: 18854871, 18651097, 17586837). It is estimated that substitutions at this codon account for 1/3 of all SOS1 mutations seen in individuals affected with Noonan syndrome (PMID: 21387466), which suggests that this codon is essential for proper SOS1 protein function. For these reasons, this variant has been classified as Pathogenic.
Fulgent Genetics,Fulgent Genetics RCV000763086 SCV000893612 pathogenic Gingival fibromatosis 1; Noonan syndrome 4 2018-10-31 criteria provided, single submitter clinical testing
Blueprint Genetics RCV000159177 SCV000927898 pathogenic not provided 2018-08-31 criteria provided, single submitter clinical testing
Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn RCV000856746 SCV000999294 pathogenic Noonan syndrome 1 criteria provided, single submitter clinical testing
Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago RCV000763086 SCV001190418 pathogenic Gingival fibromatosis 1; Noonan syndrome 4 2019-09-04 criteria provided, single submitter clinical testing SOS1 NM_005633.3 exon 10 p.Arg552Ser (c.1656G>C): This variant has been reported in the literature in several individuals with Noonan syndrome, including two cases reported to be de novo (Tartaglia 2007 PMID:17143282, Ko 2008 PMID:19020799, Beneteau 2009 PMID:19352411, Lepri 2011 PMID:21387466, Quaio 2013 PMID:24037001, Croonen 2013 PMID:23885229). This variant is not present in large control databases but is present in ClinVar, with several labs classifying this variant as pathogenic (Variation ID:12872). Evolutionary conservation and computational predictive tools suggest that this variant may impact the protein. Another variant (c.1656G>T) that gives rise to the same protein change (p.Arg552Ser) has also been reported in several individuals with Noonan syndrome (Zenker 2007 PMID:17586837, Narumi 2008 PMID:18651097, Neumann 2009 PMID:18854871). Additionally, several other variants at this amino acid position (p.Arg552Gly, p.Arg552Lys, p.Arg552Met, p.Arg552Thr, p.Arg552Trp) have also been reported in individuals with Noonan syndrome, supporting the potential functional relevance of this codon. In summary, this variant is classified as pathogenic based on the data above.
OMIM RCV000013732 SCV000033979 pathogenic Noonan syndrome 4 2008-11-15 no assertion criteria provided literature only
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000156992 SCV000206715 pathogenic Noonan syndrome 2012-06-08 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.